2018 ASCO/CAP Her2 Testing Guidelines in Breast Cancer. Impact of the Updated Guidelines on Breast Carcinomas Originally Classified as Her2 Equivocal - A Retrospective Analysis

被引:0
|
作者
Alzeer, Ali [1 ]
Zeck, Jay [1 ]
Laureano, Julio [1 ]
Sidawy, Mary [1 ]
机构
[1] MedStar Georgetown Univ Hosp, Washington, DC USA
关键词
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
108
引用
收藏
页数:2
相关论文
共 50 条
  • [31] How Do the Differences Between 2013 and 2007 ASCO/CAP HER2 Guidelines Affect Her2 Status in Breast Carcinomas?
    Onguru, Onder
    Zhang, Paul
    MODERN PATHOLOGY, 2015, 28 : 59A - 59A
  • [32] How Do the Differences Between 2013 and 2007 ASCO/CAP HER2 Guidelines Affect Her2 Status in Breast Carcinomas?
    Onguru, Onder
    Zhang, Paul
    LABORATORY INVESTIGATION, 2015, 95 : 59A - 59A
  • [33] Quality improvement analysis of HER2 FISH testing in breast cancer in response to the new ASCO/CAP guidelines
    Fang, M.
    Thalody, V
    Tannenbaum, S.
    CANCER RESEARCH, 2009, 69 (02) : 208S - 208S
  • [34] Impact of recent 2018 ASCO-CAP HER2 testing guidelines on 2713 breast cancer cases treated according to 2013 ASCO-CAP HER2 guidelines- Western Indian tertiary cancer centre experience
    Pai, Trupti
    Ankolkar, Mandar
    Shetty, Omshree
    Gurav, Mamta
    Dhanavade, Sandeep
    Tambe, Sonali
    Kadam, Vinayak
    Patil, Asawari
    Desai, Sangeeta
    Shet, Tanuja
    LABORATORY INVESTIGATION, 2019, 99
  • [35] Impact of recent 2018 ASCO-CAP HER2 testing guidelines on 2713 breast cancer cases treated according to 2013 ASCO-CAP HER2 guidelines-Western Indian tertiary cancer centre experience
    Pai, Trupti
    Ankolkar, Mandar
    Shetty, Omshree
    Gurav, Mamta
    Dhanavade, Sandeep
    Tambe, Sonali
    Kadam, Vinayak
    Patil, Asawari
    Desai, Sangeeta
    Shet, Tanuja
    MODERN PATHOLOGY, 2019, 32
  • [36] Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results
    Bo Wang
    Wei Ding
    Ke Sun
    Xiaoling Wang
    Liming Xu
    Xiaodong Teng
    Scientific Reports, 9
  • [37] Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results
    Wang, Bo
    Ding, Wei
    Sun, Ke
    Wang, Xiaoling
    Xu, Liming
    Teng, Xiaodong
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [38] Characteristics of HER2 FISH-Equivocal Breast Cancers and the Impacts on HER2 Status of 2018 ASCO/CAP Guideline
    Kong, Hui
    Bai, Qianming
    Lu, Hongfen
    Zhou, Xiaoyan
    Yang, Wentao
    LABORATORY INVESTIGATION, 2019, 99
  • [39] Characteristics of HER2 FISH-Equivocal Breast Cancers and the Impacts on HER2 Status of 2018 ASCO/CAP Guideline
    Kong, Hui
    Bai, Qianming
    Lu, Hongfen
    Zhou, Xiaoyan
    Yang, Wentao
    MODERN PATHOLOGY, 2019, 32
  • [40] HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines
    McLemore, Lauren E.
    Albarracin, Constance T.
    Gruschkus, Stephen K.
    Bassett, Roland L., Jr.
    Wu, Yun
    Dhamne, Sagar
    Yiml, Isaiah
    Lin, Kevin
    Bedrosian, Isabelle
    Sneigel, Nour
    Chen, Hui
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (01) : 95 - 104